DESMOPRESSIN ACETATE by Ferring Pharmaceuticals is clinical pharmacology desmopressin acetate tablets contain as active substance, desmopressin acetate, a synthetic analogue of the natural hormone arginine vasopressin. Approved for primary nocturnal enuresis. First approved in 2008.
Drug data last refreshed 17h ago · AI intelligence enriched 1w ago
Desmopressin acetate is a synthetic analogue of arginine vasopressin indicated for primary nocturnal enuresis, available as an oral tablet. It works by enhancing antidiuretic activity, reducing urinary output and increasing urine osmolality to control bedwetting. The oral formulation has approximately 5% bioavailability compared to intranasal administration, with onset of effect at ~1 hour and maximum effect at 4-7 hours.
As LOE approaches, the brand team will likely focus on lifecycle management and transition planning, with potential consolidation of commercial resources.
CLINICAL PHARMACOLOGY Desmopressin acetate tablets contain as active substance, desmopressin acetate, a synthetic analogue of the natural hormone arginine vasopressin. Central Diabetes Insipidus: Dose response studies in patients with diabetes insipidus have demonstrated that oral doses of 0.025 mg…
Worked on DESMOPRESSIN ACETATE at Ferring Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Desmopressin Acetate 0.2 mg Tablets, Fasting
Desmopressin acetate offers limited career growth given its LOE stage and mature market position; opportunities are concentrated in commercial teams managing market defense and competitive pricing. Roles focusing on lifecycle management, generic transition, and cost optimization will be most relevant.